EG 427 highlights at ASGCT major advances made with its HERMES platform in neurology using versatile non-replicative herpes vectorsParis, France, May 13, 2025 (GLOBE NEWSWIRE) -- EG 427 announced today data highlighting the Company’s leading role in developing non-replicating HSV-1 (nrHSV-1) vector technology in neurology. Data will be presented at the 28th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT), May 13-17, New Orleans.
Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladderParis, France, February 27, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology based on its unique HERMES vector platform, announced today that the first patient has been treated in a first-in-human, phase 1b/2a study of EG110A, a genetic medicine for the treatment of neurogenic detrusor overactivity (NDO) in people with spinal cord injury (SCI).
EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform developmentParis, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance - as part of the InnoBio investment strategy.
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical studyParis, France, June 24, 2024 – EG 427, a biotechnology company leading the development of pinpoint DNA medicines for prevalent diseases in neurology based on its unique non-replicative HSV-1 vector platform, announces today that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for EG110A, a gene therapy for the treatment of Neurogenic Detrusor Overactivity (NDO) in Spinal Cord Injury (SCI) patients. The phase 1b/2a study is being initiated in 2 leading US institutions.
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)
EG 427 announces final Series A closing, achieving €18 million in total funds raisedParis, France, 13 July, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today the final closing of a Series A financing. EG 427 raised an additional €5 million in the final closing from a combination of existing investors and new family office investors, bringing the total raised in the Series A round to €18 million.
